Pharmacyte Biotech Inc (OTCMKTS:PMCB) was a massive decliner during Tuesday’s trading session plunging by 8% on relatively high volumes, which were 1.01 times the 30 day average turnover. Bears continue to be in total control as Pharmacyte Biotech continues to form lower tops and lower bottoms indicative of the strong bearish momentum. The stock continues to trade below all moving averages.The MACD oscillators are showing signs no signs of a bullish reversal. The strength oscillator is pointing towards the stocks’ lack of inherent strength at the moment. The stock hit a fresh 52 week low during Tuesday’s trading session.
In order to strengthen its board of directors, Pharmacyte Biotech Inc (OTCMKTS:PMCB) has decided to appoint industry veteran Dr. Hans-Peter Hammes to its Scientific Advisory Board. Before accepting this proposal, Dr. Hammes worked significantly in the medical field and contributed to the studies regarding treatment of diabetes.
Road Ahead
In addition to working with the Scientific Advisory Board of Pharmacyte Biotech, Dr. Hammes has also agreed to become a consultant to the company and be a part of its International Diabetes Consortium. Company’s senior management team can’t thank enough to Dr. Hammes for accepting this position and agreeing to help the company in growing further. According to Kenneth L. Waggoner, CEO, Pharmacyte, it’s a proud moment for the company to have such an eminent personality like Dr. Hammes working with it.
The primary driving force behind this decision is the decades of experience and expertise of Dr. Hammes in the field of Diabetes. He’s one of the well-known and highly sought after experts in the medical field and can guide Pharmacyte Biotech’s staff in advance studies and research projects related to diabetes.
The kind of enthusiasm and dedication he showed towards the medical science during 2015 Annual Meeting of International Diabetes Consortium was truly commendable. There’s no single member of the consortium who thinks that Dr. Hammes has done anything that should go unnoticed in the medical science field. Pharmacyte looks forward to developing a treatment for insulin-dependent diabetes, and guidance of Dr. Hammes can prove to be innumerable in this project.
At present Dr. Hammes works as a Professor at the University of Heidelberg and looks after Internal Medicine and Endocrinology subject. He received the medical degree from Germany-based Westfälische Wilhelm-University in 1980 and has been a part of many diabetes-related studies since then.
Dr. Hammes is equally excited to get this opportunity and hopes that he will be able to use his experience and knowledge at Pharmacyte in the best possible way.
